Attendee search 

healthcare VC

AnHeart Therapeutics is an oncology-focused clinical stage biopharmaceutical company headquartered in Hangzhou, China with offices in Beijing, Shanghai and New York. The company’s pipeline consists of three clinical stage assets: Taletrectinib, a next-gen ROS1 and NTRK inhibitor currently in Phase 2; an mIDH1 inhibitor ready for Phase 2 for low grade glioma, cholangiocarcinoma, AML and other tumors; and an AXL inhibitor in Phase 1 for overcoming resistance in various tumors.

Huahai Investment Co, Ltd is a young, China-based firm backed by the Huahai Pharmaceuticals Group, a listed company in the Shanghai Stock Exchange. Our twin missions are to make investment as well as partnership deals in the healthcare sector.

A joint venture with AstraZeneca, focusing on introducing life science companies into Wuxi and develop the biopharmaceutical industry in the city.

CRO & CDMO

Illumina is a provider of Next Generation Sequencing technology

InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on lymphoma, solid tumors, and autoimmune diseases with high unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, New Jersey, and Boston.

Angine Biotech (Angine) is a international business development solution provider company dedicated in the pharma, biotech and medical device fields for the global business partnership building. We are working with our overseas' business partner to introduce the clinical and market unmet projects/products to China by leveraging the local expertise and resources. 

With the professional international BD team, the expert consultant group as well as the valuable data room for Chinese markets in the biotech and health care field, Angine is committed to provide the tailor-made solutions for the overseas’ partners who would like to explore the access to the Chinese markets. The solutions are including but not limited to the Chinese market landscape investigation, the regulatory affairs support, the reimbursement policy study, the ideal incubator and strategic biz partner recommendation, as well as the capital and talent services when the project is confirmed to settle in the referred incubator or campus.

Angine would like work with you as a strategic partner to co-develop the Chinese healthcare market, to make your ideas or IP become the products by inputting the expertise from both sides.

You can write an email to leoluo@anginebio.com for your ideas and proposals for the Chinese markets. Let our team give you a solution.

Guangzhou Wondfo Biotech Co., Ltd., headquartered in Guangzhou science city, has been focusing on the R&D, production, sales and service of point-of-care testing (POCT) products and providing customers with professional rapid diagnosis and chronic disease management solutions since founded in 1992. Wondfo now has more than 3000 employees and a wide range of products for the rapid identification of cardiovascular diseases, inflammation, tumor, infectious diseases, drug abuse, pregnancy, and so on, widely sold to 140+ countries and regions.

MEDICAL AND MEDICINE INTL COOPAERATION AND INVESTMENT